Traws Pharma, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Steven M Fruchtman. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Steven M Fruchtman has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ONTX / Onconova Therapeutics, Inc. PRESIDENT, CHIEF EXECUTIVE OFF, Director 74,792
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Steven M Fruchtman. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases TRAW / Traws Pharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TRAW / Traws Pharma, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-09-28 ONTX Fruchtman Steven M 2,381 4.2000 95 105.0000 10,000 1 3.87 -9,632 -96.32
2021-02-16 ONTX Fruchtman Steven M 20,000 1.0000 1,000 20.0000 20,000
2020-11-25 ONTX Fruchtman Steven M 40,000 0.2590 2,000 5.1800 10,360
2020-05-19 ONTX Fruchtman Steven M 26,800 0.3678 1,340 7.3560 9,857
2019-11-25 ONTX Fruchtman Steven M 149,000 0.2000 7,450 4.0000 29,800

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRAW / Traws Pharma, Inc. Insider Trades
Insider Sales TRAW / Traws Pharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TRAW / Traws Pharma, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRAW / Traws Pharma, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Steven M Fruchtman as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-03-15 2024-03-14 4 ONTX Onconova Therapeutics, Inc.
Common Stock
F - Taxes -8,727 74,792 -10.45 0.90 -7,854 67,313
2024-03-15 2024-03-13 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise 23,111 83,519 38.26
2024-02-09 2024-02-07 4 ONTX Onconova Therapeutics, Inc.
Common Stock
F - Taxes -9,212 60,408 -13.23 0.67 -6,172 40,473
2024-02-09 2024-02-07 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise 21,320 69,620 44.14
2023-08-04 2023-08-03 4 ONTX Onconova Therapeutics, Inc.
Common Stock
F - Taxes -4,744 48,300 -8.94 1.01 -4,791 48,783
2023-08-04 2023-08-02 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise 12,567 53,044 31.05
2023-02-08 2023-02-07 4 ONTX Onconova Therapeutics, Inc.
Common Stock
F - Taxes -6,977 40,477 -14.70 1.36 -9,489 55,049
2023-02-08 2023-02-07 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise 21,320 47,454 81.58
2022-08-04 2022-08-03 4 ONTX Onconova Therapeutics, Inc.
Common Stock
F - Taxes -4,562 26,134 -14.86 1.32 -6,022 34,497
2022-08-04 2022-08-02 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise 12,566 30,696 69.31
2022-02-09 2022-02-07 4 ONTX Onconova Therapeutics, Inc.
Restricted Stock Units
A - Award 63,960 63,960
2022-02-09 2022-02-07 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 191,880 191,880
2021-09-28 2021-09-28 4 ONTX Onconova Therapeutics, Inc.
Common Stock
P - Purchase 2,381 18,130 15.12 4.20 10,000 76,146
2021-08-04 2021-08-02 4 ONTX Onconova Therapeutics, Inc.
Restricted Stock Unit
A - Award 37,700 37,700
2021-08-04 2021-08-02 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 113,000 113,000
2021-02-19 2021-02-17 4 ONTX Onconova Therapeutics, Inc.
Stock Appreciation Right
A - Award 706,000 706,000
2021-02-17 2021-02-16 4 ONTX Onconova Therapeutics, Inc.
Common Stock
P - Purchase 20,000 236,226 9.25 1.00 20,000 236,226
2020-11-30 2020-11-25 4 ONTX Onconova Therapeutics, Inc.
Common Stock
P - Purchase 40,000 216,226 22.70 0.26 10,360 56,003
2020-07-10 2020-07-09 4 ONTX Onconova Therapeutics, Inc.
Stock Appreciation Right
A - Award 1,273,800 1,273,800
2020-05-20 2020-05-19 4 ONTX Onconova Therapeutics, Inc.
Common Stock
P - Purchase 26,800 176,226 17.94 0.37 9,857 64,816
2019-12-26 2019-12-20 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 200,000 200,000
2019-11-26 2019-11-25 4 ONTX Onconova Therapeutics, Inc.
Warrant (right to purchase)
P - Purchase 149,000 149,000
2019-11-26 2019-11-25 4 ONTX Onconova Therapeutics, Inc.
Common Stock
P - Purchase 149,000 149,426 34,976.53 0.20 29,800 29,885
2018-07-30 2018-07-26 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 400,000 400,000
2018-01-05 2018-01-03 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 43,627 43,627
2017-01-19 2017-01-17 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 26,401 26,401
2016-12-19 2016-12-15 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 7,599 7,599
2016-09-01 2016-09-01 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 25,000 25,000
2016-08-10 2016-07-29 4 ONTX Onconova Therapeutics, Inc.
Warrants (right to buy)
X - Other 4,706 4,706
2016-08-10 2016-07-29 4 ONTX Onconova Therapeutics, Inc.
Common Stock
X - Other 6,276 6,376 6,276.00 4.10 25,732 26,142
2016-08-10 2016-07-26 4 ONTX Onconova Therapeutics, Inc.
Subscription Rights(right to buy)
X - Other -150 0 -100.00
2016-06-30 2016-06-24 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -100 12,411 -0.80
2016-06-30 2016-06-24 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise 100 100 6.50 650 650
2016-01-28 2016-01-26 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 125,107 125,107
2015-10-01 2015-09-25 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 40,000 40,000
2015-04-22 2015-04-20 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 35,000 35,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)